Eneida Rejane Rabelo da Silva

Two HEmostasis Methods After TransradIal Catheterization: THEMATIC - protocol for a randomized clinical trial.

OBJECTIVE Randomized clinical trial protocol to evaluate the incidence of radial artery occlusion with two different arterial compression devices after transradial procedures. METHODS Barbeaus test will be performed in adults scheduled to undergo transradial interventional procedures. Those with A, B, or C plethysmographic patterns will be selected. At the end of the procedure, patients will be randomly assigned (1:1) to receive patent haemostasis with TR Band™ device or conventional haemostasis with an elastic adhesive bandage. The primary outcome is the incidence of radial artery occlusion. Secondary outcomes are Barbeaus test curve change, additional time to achieve haemostasis, incidence of bleeding at the puncture site, pain severity, development of arteriovenous fistula, radial pseudo aneurysm, any access-site complication requiring vascular surgery intervention and costs between the two devices. DISCUSSION The results of this trial should provide valuable additional information on the best approach for haemostasis after transradial percutaneous cardiovascular interventions.

Trastuzumab-resistant HER2-positive metastatic breast cancer: Comparing results of lapatinib and capecitabine in brain and other metastatic sites.

e11505 Background: Trastuzumab, anthracycline, and taxane resistant HER2-positive metastatic breast cancer has poor prognosis. Progression in brain metastasis (BM) commonly leads to difficult diagnostic interpretation and treatment decisions, poor quality of life, and death. Methods: Consented patients (pts) with HER2-positive metastatic breast cancer, ECOG ≤2, with resistance to trastuzumab, taxane, and anthracyclines, were recruited for treatment with daily lapatinib (L) (1,250 mg daily) and capecitabine (C) (2,000 mg/m2/day days 1-14) in a 21 day cycle. Progression was evaluated by RECIST and statistics by SPSS. Results: We enrolled 10 pts (median age 44), median follow up was 19.51 months (M). One patient had grade 3 toxicity due to C and was kept with L only; no other patient discontinued L nor C due to toxicity. Nine (90%) pts had ≥2 metastatic sites, one pt had BM only, and 6 pts had BM in addition to other sites. Median time to progression (TTP) was 9.10 M for the 10 pts, 13.86 M for BM as site of...